33,431 reports of this reaction
4.3% of all DUPILUMAB reports
#4 most reported adverse reaction
RASH is the #4 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 33,431 FDA adverse event reports linking DUPILUMAB to RASH. This represents approximately 4.3% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among DUPILUMAB users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 33,431 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 4.3% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience rash while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.